Table 1.

Primary and Secondary Endpoints of Eyes with Neovascular Age-Related Macular Degeneration Treated with an Escalating Dose of Levodopa Through 6 Months

Change from Baseline at Month-6	Cohort 1 (n = 15)	Cohort 2 (n = 11)
Change in BCVA (letters)
Mean ± SE	4.7 ± 1.4	4.8 ± 1.5
95% CI for mean	(1.8–7.7)	(1.4–8.2)
Median	5.0	5.0
P value	.004*	.02†
Change in CRT (μm)
Mean ± SE	−51.4 ± 19.2	4.0 ± 9.5
95% CI for mean	(−92.7 to −10.1)	(−17.1–25.1)
Median	−31.0	−3.0
P value	.01*	ns*
Change in retinal fluid (%)
Mean ± SE	−41 ± 13.4	3.7 ± 35.5
95% CI for mean	(−69.6 to −12)	(−75.3–82.7)
Median	−43.5	−12.8
P value	.01‡	ns§

BCVA = best-corrected visual acuity, measured with the use of the Early Treatment Diabetic Retinopathy Study protocol at 7 m; CI = confidence interval; CRT = central retinal thickness; SE = standard error.

^*Wilcoxon matched-pairs signed rank analysis.

^†Paired-sample t test.

^‡One-sample t test.

^§One-sample Wilcoxon signed rank test. Data meeting the criterion of a normal distribution were compared with parametric Student’s t tests. In case of non-parametric testing, Wilcoxon matched-pairs signed rank tests were applied.